Notably, given our observation that PTGES/PTGES2 mRNA expression (as well as PC mRNA in some cases) is increased in post-progression biopsies from melanoma patients treated with vemurafenib or dabrafenib, there is potential for altered metabolic programs, as we have described, to contribute to the acquisition of BRAF-inhibitor resistance in patients. The gene discussed is BRAF; the disease is melanoma.